Rein Therapeutics (RNTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.63, +7.17% vs the prior close of $0.59.
- Volume 1.37M shares, 3.2x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RNTX jumps 7.2% to $0.63 on 3.2x normal volume. Closed at $0.63, +7.17% vs the prior close of $0.59. Day range $0.55–$0.67, opened at $0.60.
RNTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RNTX jumps 7.2% to $0.63 on 3.2x normal volume
- Closed at $0.63, +7.17% vs the prior close of $0.59. Day range $0.55–$0.67, opened at $0.60.
- Volume was 1.37M shares, 3.2x its 50-day average of 434.55K — unusually heavy trading.
- Price is -19.9% vs its 50-day average ($0.78) and -41.3% vs its 200-day average ($1.07).
- 52-week range $0.54–$2.18; today's close sits at 5% of that range, 71.2% below the 52-week high.
Oct 14, 2026 — RNTX slides 22.4% to $0.59, a 52-week low on 2.7x normal volume
- Closed at $0.59, -22.38% vs the prior close of $0.75. Day range $0.54–$0.75, opened at $0.75.
- Volume was 1.14M shares, 2.7x its 50-day average of 421.36K — unusually heavy trading.
- Price is -25.4% vs its 50-day average ($0.79) and -45.3% vs its 200-day average ($1.07).
- 52-week range $0.54–$2.18; today's close sits at 3% of that range, 73.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — RNTX slides 3.8% to $0.75
- Closed at $0.75, -3.82% vs the prior close of $0.79. Day range $0.75–$0.78, opened at $0.78.
- Volume was 142.50K shares, 0.3x its 50-day average of 421.29K — lighter than usual.
- Price is -4.4% vs its 50-day average ($0.79) and -29.8% vs its 200-day average ($1.07).
- 52-week range $0.69–$2.18; today's close sits at 4% of that range, 65.4% below the 52-week high.
Oct 12, 2026 — RNTX dips 1.1% to $0.79
- Closed at $0.79, -1.13% vs the prior close of $0.79. Day range $0.75–$0.79, opened at $0.77.
- Volume was 108.10K shares, 0.3x its 50-day average of 426.97K — lighter than usual.
- Price is -0.5% vs its 50-day average ($0.79) and -27.2% vs its 200-day average ($1.08).
- 52-week range $0.69–$2.18; today's close sits at 6% of that range, 64.0% below the 52-week high.
Oct 9, 2026 — RNTX jumps 3.3% to $0.79
- Closed at $0.79, +3.25% vs the prior close of $0.77. Day range $0.76–$0.81, opened at $0.76.
- Volume was 307.50K shares, 0.7x its 50-day average of 424.46K.
- Price is +0.7% vs its 50-day average ($0.79) and -26.5% vs its 200-day average ($1.08).
- 52-week range $0.69–$2.18; today's close sits at 7% of that range, 63.6% below the 52-week high.
Oct 8, 2026 — RNTX dips 2.5% to $0.77, 3 down days in a row
- Closed at $0.77, -2.53% vs the prior close of $0.79. Day range $0.75–$0.78, opened at $0.78.
- Volume was 477.60K shares, 1.1x its 50-day average of 419.21K.
- Price is -2.4% vs its 50-day average ($0.79) and -29.0% vs its 200-day average ($1.08).
- 52-week range $0.69–$2.18; today's close sits at 5% of that range, 64.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — RNTX slides 4.4% to $0.79
- Closed at $0.79, -4.36% vs the prior close of $0.82. Day range $0.78–$0.82, opened at $0.80.
- Volume was 447.00K shares, 1.0x its 50-day average of 426.95K.
- Price is +0.2% vs its 50-day average ($0.79) and -27.4% vs its 200-day average ($1.09).
- 52-week range $0.69–$2.18; today's close sits at 6% of that range, 63.8% below the 52-week high.
Oct 6, 2026 — RNTX ends flat (+0.0%) to $0.82
- Closed at $0.82, +0.00% vs the prior close of $0.82. Day range $0.81–$0.83, opened at $0.82.
- Volume was 185.60K shares, 0.4x its 50-day average of 429.97K — lighter than usual.
- Price is +4.8% vs its 50-day average ($0.79) and -24.3% vs its 200-day average ($1.09).
- 52-week range $0.69–$2.18; today's close sits at 9% of that range, 62.2% below the 52-week high.
Oct 5, 2026 — RNTX rises 3.0% to $0.82
- Closed at $0.82, +3.00% vs the prior close of $0.80. Day range $0.81–$0.87, opened at $0.81.
- Volume was 336.10K shares, 0.8x its 50-day average of 430.09K.
- Price is +4.9% vs its 50-day average ($0.79) and -24.4% vs its 200-day average ($1.09).
- 52-week range $0.69–$2.18; today's close sits at 9% of that range, 62.2% below the 52-week high.
Oct 2, 2026 — RNTX slides 6.0% to $0.80
- Closed at $0.80, -5.99% vs the prior close of $0.85. Day range $0.78–$0.86, opened at $0.85.
- Volume was 480.50K shares, 1.1x its 50-day average of 447.39K.
- Price is +1.9% vs its 50-day average ($0.79) and -26.8% vs its 200-day average ($1.09).
- 52-week range $0.69–$2.18; today's close sits at 7% of that range, 63.3% below the 52-week high.
RNTX latest news & SEC filings
Every SEC filing by or about RNTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$6.38M (prior year -$6.82M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.10 (prior year -$0.28) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jul 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RNTX
- Last results release: May 15, 2025 (8-K Item 2.02). Previous ones: Nov 14, 2024, Aug 14, 2024, May 15, 2024. Based on that rhythm, the next report is likely around Aug 14, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.18% (largest 22.4%). That is a volatile stock.
- Liquidity: about 434.38K shares (≈$272.79K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.63 vs a range of $0.54–$2.18 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Rickenbach Josef H Von bought 4,500 shares on May 27, 2026.
- Latest filings: 8-K Sep 4, 2026; 8-K Aug 27, 2026; 10-Q Aug 14, 2026.
- Share count: 86.27M shares outstanding (Aug 12, 2026), +270.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RNTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.60 | 0.67 | 0.55 | 0.63 | 1.37M |
| Oct 14, 2026 | 0.75 | 0.75 | 0.54 | 0.59 | 1.14M |
| Oct 13, 2026 | 0.78 | 0.78 | 0.75 | 0.75 | 142.50K |
| Oct 12, 2026 | 0.77 | 0.79 | 0.75 | 0.79 | 108.10K |
| Oct 9, 2026 | 0.76 | 0.81 | 0.76 | 0.79 | 307.50K |
| Oct 8, 2026 | 0.78 | 0.78 | 0.75 | 0.77 | 477.60K |
| Oct 7, 2026 | 0.80 | 0.82 | 0.78 | 0.79 | 447.00K |
| Oct 6, 2026 | 0.82 | 0.83 | 0.81 | 0.82 | 185.60K |
| Oct 5, 2026 | 0.81 | 0.87 | 0.81 | 0.82 | 336.10K |
| Oct 2, 2026 | 0.85 | 0.86 | 0.78 | 0.80 | 480.50K |
| Oct 1, 2026 | 0.80 | 0.90 | 0.76 | 0.85 | 1.11M |
| Sep 30, 2026 | 0.80 | 0.83 | 0.76 | 0.80 | 419.00K |
| Sep 29, 2026 | 0.72 | 0.81 | 0.72 | 0.79 | 388.40K |
| Sep 28, 2026 | 0.76 | 0.79 | 0.72 | 0.72 | 162.80K |
| Sep 25, 2026 | 0.74 | 0.82 | 0.73 | 0.75 | 112.80K |
| Sep 24, 2026 | 0.77 | 0.79 | 0.71 | 0.74 | 296.30K |
| Sep 23, 2026 | 0.79 | 0.82 | 0.77 | 0.77 | 441.40K |
| Sep 22, 2026 | 0.81 | 0.82 | 0.79 | 0.80 | 87.10K |
| Sep 21, 2026 | 0.81 | 0.81 | 0.79 | 0.80 | 178.20K |
| Sep 18, 2026 | 0.79 | 0.82 | 0.78 | 0.80 | 492.50K |
About Rein Therapeutics
Rein Therapeutics (RNTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in AUSTIN, TX. Fiscal year ends December 31. SEC CIK 1420565.
RNTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Rickenbach Josef H Von | Director | May 28, 2026 |
| James Brian Windsor | See Remarks | May 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Brian Windsor | See Remarks | May 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 27, 2026 | Rickenbach Josef H Von | Buy | 4,500 | $1.07 |
| May 26, 2026 | Rickenbach Josef H Von | Buy | 23,190 | $1.06 |
| May 22, 2026 | Rickenbach Josef H Von | Buy | 15,950 | $1.05 |
| May 21, 2026 | Rickenbach Josef H Von | Buy | 3,420 | $1.04 |
| Apr 30, 2026 | James Brian Windsor | Buy | 25,000 | $1.00 |
| Nov 14, 2025 | Value Master Fund, Lp Voss | Buy | 104,183 | $1.22 |
| Nov 14, 2025 | Advisors Gp, Llc Voss | Buy | 104,183 | $1.22 |
| Nov 14, 2025 | Travis W. Cocke | Buy | 104,183 | $1.22 |
| Nov 14, 2025 | Value-Oriented Special Situations Fund, Lp Voss | Buy | 104,183 | $1.22 |
| Nov 14, 2025 | Capital, Lp Voss | Buy | 104,183 | $1.22 |
| Oct 28, 2025 | Value-Oriented Special Situations Fund, Lp Voss | Buy | 178,392 | $1.39 |
| Oct 28, 2025 | Capital, Lp Voss | Buy | 178,392 | $1.39 |
| Oct 28, 2025 | Advisors Gp, Llc Voss | Buy | 178,392 | $1.39 |
| Oct 28, 2025 | Travis W. Cocke | Buy | 178,392 | $1.39 |
| Oct 28, 2025 | Value Master Fund, Lp Voss | Buy | 178,392 | $1.39 |
RNTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-49.87M | -1.96 | $-19.36M |
| Dec 31, 2024 | $0 | $-62.88M | -3.51 | $-22.29M |
| Dec 31, 2023 | $0 | $-15.73M | -3.42 | $-19.81M |
| Dec 31, 2022 | $0 | $-27.33M | -6.02 | $-24.86M |
| Dec 31, 2021 | $0 | $-26.16M | -5.89 | $-23.75M |
Latest balance sheet: total assets $65.97M, total liabilities $10.77M, cash $8.54M (as of Jun 30, 2026).
RNTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| May 15, 2025 | 8-K Item 2.02 (results) | $2.36 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $3.31 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Apr 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RNTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.